DSC127, an analog of Angiotensin II. The patented amino acid peptide optimizes the wound healing capabilities of Angiotensin II while removing all blood pressure effects of the compound. The result is a novel drug shown in pre-clincal testing to:

• Increase keratinocyte proliferation
• Increase extracellular matrix production
• Increase vascularization.

All these help to accelerate dermal tissue repair.  One potential method of action is the up-regulation of mesenchymal stem cells (MSCs) at the site of injury.  MSCs originate in the human embryo and are considered to be multipotent — a type of stem cell that has not yet adopted a specific cellular phenotype.  Such cells have the ability to differentiate into various types of cells found within the human body, including fibroblasts, adipose cells, muscle cells, bone cells, and skin cells.

Additionally, histological examination showed that DSC127 accelerated collagen deposition six-fold and increased the number of blood vessels at the wound site three-fold.

Placebo	DSC127
DSC127 accelerates formation of granulation tissue and blood vessels
Placebo	DSC127
DSC127 increases Collagen III deposition

This breadth of activity is likely responsible for the pre-clinical results exhibited thus far, including studies showing:

• Improved in-growth of host tissue into artificial skins (Apligraf, Integra, Dermagraft)
• Accelerated healing in a full thickness skin excision wounds in rats and diabetic mice
• Accelerated healing in partial thickness thermal injuries in guinea pigs
• Accelerated healing in a random flap skin model in rats
• Improved scar reduction in rats